Related Experiment Videos
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
1Neurology, G.B.Pant Hospital, New Delhi, D-II / 103, Kidwai Nagar-West, New Delhi-110023, New Delhi, India, 110023. mmehndi@ndf.vsnl.net.in
The Cochrane Database of Systematic Reviews
|November 1, 2001
Summary
Corticosteroids may improve impairment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but evidence is limited. Long-term risks and benefits require further study.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune peripheral neuropathy.
- Corticosteroids are often used for CIDP, with non-randomized studies suggesting benefit.
Purpose of the Study:
- To evaluate the efficacy of corticosteroids in treating chronic inflammatory demyelinating polyradiculoneuropathy.
Main Methods:
- A systematic search for randomized controlled trials (RCTs) of corticosteroid treatment for CIDP was conducted.
- The primary outcome measure was the change in disability 12 weeks after randomization.
- Secondary outcomes included changes in impairment, nerve conduction velocity, and side effects.
Main Results:
- One RCT involving 35 participants was identified.
- Corticosteroid-treated patients showed more improvement in impairment after 12 weeks compared to untreated controls.
- Non-randomized studies suggest steroids are beneficial for CIDP.
Conclusions:
- A single RCT provides weak evidence that oral corticosteroids reduce impairment in CIDP.
- The long-term risks and benefits of corticosteroid treatment for CIDP have not been adequately studied.
- Further research is needed to establish the long-term safety and efficacy of corticosteroids for CIDP.